Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Which tocolytics should be used in 2001?].

B Carbonne1, V Tsatsaris, V Lejeune

  • 1Service de Gynécologie, Obstétrique, Hôpital Saint Antoine, 184, rue du Faubourg-Saint-Antoine, 75012 Paris. bruno.carbonne@sat.ap-hop-paris.fr

Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction
|March 10, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspirin-related hemorrhagic complications in pregnancy: a nationwide French cohort study (ASPREG).

Scientific reports·2026
Same author

Posttraumatic stress disorder after second-trimester medical termination of pregnancy.

American journal of obstetrics and gynecology·2026
Same author

sFlt-1/PlGF ratio use does not reduce hospitalisation duration in suspected preeclampsia: the PRECOG study, a multicentre randomised trial.

Scientific reports·2025
Same author

Severe postpartum hemorrhage and the risk of adverse maternal outcome: A comparative analysis of two population-based studies in France and the Netherlands.

Preventive medicine reports·2024
Same author

Non-invasive cell-free DNA prenatal screening for trisomy 21 as part of primary screening strategy in twin pregnancy.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2023
Same author

[Simulation training for French obstetrics and gynecology residents: A national survey in 2022].

Gynecologie, obstetrique, fertilite & senologie·2023
Same journal

[Neuroprotection for preterm infants with antenatal magnesium sulphate].

Journal de gynecologie, obstetrique et biologie de la reproduction·2017
Same journal

[Is universal screening for cervical length among singleton pregnancies with no history of preterm birth justified?]

Journal de gynecologie, obstetrique et biologie de la reproduction·2017
Same journal

[Lifestyle recommendations for prevention of spontaneous preterm birth in asymptomatic pregnant women].

Journal de gynecologie, obstetrique et biologie de la reproduction·2017
Same journal

[Guidelines for clinical practice: Prevention of spontaneous preterm birth (excluding preterm premature rupture of membranes) - Introduction].

Journal de gynecologie, obstetrique et biologie de la reproduction·2017
Same journal

[Psychological aspects of abortion].

Journal de gynecologie, obstetrique et biologie de la reproduction·2016
Same journal

[Induced abortion: Guidelines for clinical practice - Introduction].

Journal de gynecologie, obstetrique et biologie de la reproduction·2016
See all related articles

New tocolytics like calcium-channel blockers offer comparable pregnancy extension to beta-mimetics with fewer side effects and improved neonatal outcomes, suggesting a shift in preterm birth treatment.

Area of Science:

  • Obstetrics and Gynecology
  • Pharmacology
  • Neonatal Medicine

Background:

  • Beta-mimetics are standard tocolytic agents for preterm birth but have significant maternal risks and unproven neonatal benefits.
  • Predictive criteria for preterm birth are lacking, leading to widespread unnecessary treatment.
  • There is a clinical need for tocolytic therapies with improved safety profiles and demonstrable neonatal advantages.

Purpose of the Study:

  • To evaluate alternative tocolytic agents, specifically calcium-channel blockers and oxytocin antagonists, as first-line treatments for preterm birth.
  • To compare the efficacy and safety of these newer agents against traditional beta-mimetics.
  • To assess the impact of different tocolytic strategies on neonatal outcomes.

Main Methods:

Related Experiment Videos

  • Review of randomized trials comparing calcium-channel blockers and oxytocin antagonists with beta-mimetics.
  • Meta-analysis of trials focusing on pregnancy prolongation, maternal adverse effects, and neonatal outcomes.
  • Analysis of data on emerging tocolytic compounds like NO donors and cyclooxygenase-2 inhibitors.

    • Main Results:

    • Calcium-channel blockers and oxytocin antagonists demonstrate comparable efficacy to beta-mimetics in prolonging pregnancy by 48 hours.
    • These alternative agents exhibit better maternal tolerance, reducing treatment interruptions due to side effects.
    • Meta-analysis indicates a reduction in neonatal respiratory distress syndrome and NICU admissions with calcium-channel blockers compared to beta-mimetics.

    Conclusions:

    • Calcium-channel blockers and oxytocin antagonists represent a safer and potentially more effective first-line tocolytic strategy than beta-mimetics.
    • These agents offer improved maternal safety and significant neonatal benefits, including reduced respiratory distress.
    • Further research into NO donors and COX-2 inhibitors may yield additional therapeutic options for preterm birth management.